Undisclosed · Healthtech
SwissHealth Ventures invests in hormone-tracking startup inne
CSS’s venture arm backs the German developer of saliva-based progesterone monitoring for women’s health.
SwissHealth Ventures has invested in inne, the German company behind a saliva-based hormone-tracking system. CSS announced the investment on 24 September 2026 without disclosing its size.
inne’s Minilab combines test strips, a reader and an app to measure progesterone and show cycle patterns. The company serves women seeking hormone information for fertility planning, cycle understanding and hormone-free contraception.
For SwissHealth Ventures, the investment extends its work in preventive women’s health. The investor’s portfolio identifies inne founders Eirini Rapti and Hicham Ratnani and confirms that it became a shareholder in 2026.
Funding history
Undisclosed · This roundUndisclosed